ClinicalTrials.gg
RecruitingNCT07615426KAPPTIVATE1001Updated Nov 3, 2026

A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

A Phase 1 interventional study of Aticaprant and Placebo in Schizophrenia, sponsored by Janssen Research & Development, LLC. Recruiting at 8 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 3, 2026Site recruiting status changedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Schizophrenia by Johnson & Johnson — 2 open to participants now, 2 under way, 1 of them phase 3. Schizophrenia · Johnson & Johnson.

Planned enrollment
121st of 176
64 · median 165
Started
2026
the only one that year
Phase 1
42 of 206
1 open now
Registered
206th of 206
by date

Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 121st largest by planned enrollment of the 176 interventional ones that give a count, is the only one that started in 2026, is one of 42 in phase 1, and was the 206th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 206 studies in Schizophrenia by Johnson & Johnson are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Schizophrenia by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically stable with a diagnosis of schizophrenia confirmed by the mini international neuropsychiatric interview [MINI] for psychotic disorders
  • The participant must be on a stable dose of only one atypical antipyschotic medication
  • Must be receiving outpatient treatment for schizophrenia from a psychiatric provider at the time of screening
  • At the Baseline visit, must have a presence of permitted background antipsychotic medication based on blood samples drawn at the screening visit
  • If taking an antidepressant or anxiolytic, no dose changes are allowed to have occurred within 8 weeks prior to screening or throughout the double blind treatment phase

Exclusion criteria

Exclusion criteria:

  • Has one or more of the current or prior (lifetime) (5th edition) (DSM-5) diagnoses (based on the MINI for psychotic disorders): intellectual disability, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, delusional disorder, psychotic disorder not otherwise specified (NOS), substance-induced psychotic disorder, bipolar disorder, major depressive disorder (recurrent or current episode)
  • Has a history of moderate-to-severe substance use disorder, including alcohol use disorder, according to DSM-5 criteria within 6 months before screening except for nicotine or caffeine (based on the MINI and clinical judgment)
  • Current cannabis (marijuana, pot, grass, hash, etcetera) use exceeds 3 to 5 times over the past 30 days as measured by items from the national survey on drug use and health (NSDUH) questionnaire
  • Has a history in the past 6 months of a peptic ulcer, or lifetime history of upper gastrointestinal bleeding, or known untreated helicobacter pylori infection, or has a diagnosis of zollinger-ellison syndrome (ZES)
  • Has current homicidal ideation/intent, per the investigator's clinical judgment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Arm A: Aticaprant

    Participants will receive aticaprant during the double blind (DB) treatment phase.

    Drug: Aticaprant

  • Placebo comparator
    Arm B: Placebo

    Participants will receive placebo during the DB treatment phase.

    Drug: Placebo

Interventions

  • Participants will receive aticaprant during the double blind (DB) treatment phase.

    Also known as: JNJ-67953964

  • DrugPlacebo

    Participants will receive placebo during the DB treatment phase.

06

What researchers measure

Primary outcomes

  1. Screen Pass Rate

    Screening pass rate of participants will be reported.

    Time frame: Up to 28 days

  2. Exploratory Assessment-Specific Completion Rate

    Assessment specific completion rate of participants will be reported.

    Time frame: Up to 126 days

  3. Total Assessment Completion Rate

    Time frame: Up to 126 days

  4. Study Completion Rate

    Time frame: Up to 126 days

  5. Adverse Events (AEs) Including AEs of Special Interest (AESI)

    Time frame: Up to 126 days

  6. Number of Participants with Abnormalities in Vital Signs

    Time frame: Up to 126 days

  7. Number of Participants with Abnormalities in 12-lead Electrocardiogram (ECG)

    Time frame: Up to and including 85 days

  8. Number of Participants with Abnormalities in Laboratory Parameters

    Time frame: Up to and including 85 days

  9. Number of Participants Reporting Changes in Body Weight

    Time frame: Up to and including 85 days

  10. Number of Participants Reporting Changes in Body Mass Index (BMI)

    Time frame: Up to and including 85 days

  11. Suicidality Using the Columbia Suicide Severity Rating Scale (C-SSRS) Over Time

    The C-SSRS is a clinical interview providing a summary of both ideation and behavior that can be administered during any evaluation or risk assessment to identify the occurrence and intensity of suicidal thoughts and suicidal behaviors.

    Time frame: Up to 126 days

  12. Extrapyramidal Symptoms (EPS) Assessment Using the Modified Simpson-Angus Scale (MSAS) Total Score

    Time frame: Up to and including 85 days

07

Study locations

7 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.jnj.com

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 15 months is above that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2027 → Dec 2027, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
May 29, 2026
StartActual
Mar 2, 2026
Primary completionEst.
Jun 21, 2027
CompletionEst.
Dec 3, 2027was Jul 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Western Michigan University is now Completed
Nov 3, 2026
Study completion
Jul 5, 2027→Dec 3, 2027
Oct 28, 2026
Eligibility
Maximum age 55 Years→60 Years
Oct 28, 2026
Primary outcomes
5 time frame changed
What changed in the outcomes
  • Time frameNumber of Participants with Abnormalities in 12-lead Electrocardiogram (ECG)Up to 84 days → Up to and including 85 days
  • Time frameNumber of Participants with Abnormalities in Laboratory ParametersUp to 84 days → Up to and including 85 days
  • Time frameNumber of Participants Reporting Changes in Body WeightUp to 84 days → Up to and including 85 days
  • Time frameNumber of Participants Reporting Changes in Body Mass Index (BMI)Up to 84 days → Up to and including 85 days
  • Time frameExtrapyramidal Symptoms (EPS) Assessment Using the Modified Simpson-Angus Scale (MSAS) Total ScoreUp to 84 days → Up to and including 85 days
Oct 28, 2026
Show all 3 updates
  1. Nov 3, 2026
    Western Michigan University is now Completed
    + 1 other change: verification date
  2. Oct 28, 2026
    Study completion Jul 5, 2027→Dec 3, 2027
    Eligibility Maximum age 55 Years→60 Years
    Primary outcomes 5 time frame changed
    What changed in the outcomes
    • Time frameNumber of Participants with Abnormalities in 12-lead Electrocardiogram (ECG)Up to 84 days → Up to and including 85 days
    • Time frameNumber of Participants with Abnormalities in Laboratory ParametersUp to 84 days → Up to and including 85 days
    • Time frameNumber of Participants Reporting Changes in Body WeightUp to 84 days → Up to and including 85 days
    • Time frameNumber of Participants Reporting Changes in Body Mass Index (BMI)Up to 84 days → Up to and including 85 days
    • Time frameExtrapyramidal Symptoms (EPS) Assessment Using the Modified Simpson-Angus Scale (MSAS) Total ScoreUp to 84 days → Up to and including 85 days
    + 1 other change: verification date
  3. Sep 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07615426
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Mar 2, 2026
Primary completion
Jun 21, 2027 (estimated)
Completion
Dec 3, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aticaprant

Start the discussion